keyword
MENU ▼
Read by QxMD icon Read
search

Precision oncology

keyword
https://www.readbyqxmd.com/read/29691287/systematic-modelling-and-design-evaluation-of-unperturbed-tumour-dynamics-in-xenografts
#1
Zinnia P Patricia Parra Guillen, Victor Mangas Sanjuan, Maria Garcia-Cremades, Inaki F Troconiz, Gary Mo, Celine Pitou, Philip W Iversen, Johan E Wallin
Xenograft mice are largely used to evaluate the efficacy of oncological drugs during preclinical phases of drug discovery and development. Mathematical models provide a useful tool to quantitatively characterise tumour growth dynamics and also optimise upcoming experiments. To the best of our knowledge, this is the first report where unperturbed growth of a large set of tumour cell lines (n=28) has been systematically analysed using the model proposed by Simeoni in the context of non-linear mixed effect (NLME)...
April 24, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29691075/estro-acrop-guideline-interstitial-multi-catheter-breast-brachytherapy-as-accelerated-partial-breast-irradiation-alone-or-as-boost-gec-estro-breast-cancer-working-group-practical-recommendations
#2
Vratislav Strnad, Tibor Major, Csaba Polgar, Michael Lotter, Jose-Luis Guinot, Cristina Gutierrez-Miguelez, Razvan Galalae, Erik Van Limbergen, Benjamin Guix, Peter Niehoff, Kristina Lössl, Jean-Michel Hannoun-Levi
PURPOSE: This consensus statement from the Breast Cancer Working Group of Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO) aims at generating practical guidelines for multi-catheter image-guided brachytherapy in the conservative management of breast cancer patients used for either Accelerated Partial Breast Irradiation (APBI) or for a breast boost. METHODS: Recent advances in techniques of multi-catheter brachytherapy were summarized and all the relevant literature was reviewed by a panel of experts...
April 21, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29685789/integrative-epi-genomic-analysis-to-predict-response-to-androgen-deprivation-therapy-in-prostate-cancer
#3
Sukanya Panja, Sheida Hayati, Nusrat J Epsi, James Scott Parrott, Antonina Mitrofanova
Therapeutic resistance is a central problem in clinical oncology. We have developed a systematic genome-wide computational methodology to allow prioritization of patients with favorable and poor therapeutic response. Our method, which integrates DNA methylation and mRNA expression data, uncovered a panel of 5 differentially methylated sites, which explain expression changes in their site-harboring genes, and demonstrated their ability to predict primary resistance to androgen-deprivation therapy (ADT) in the TCGA prostate cancer patient cohort (hazard ratio = 4...
April 12, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29681544/dissecting-the-contributions-of-cooperating-gene-mutations-to-cancer-phenotypes-and-drug-responses-with-patient-derived-ipscs
#4
Chan-Jung Chang, Andriana G Kotini, Malgorzata Olszewska, Maria Georgomanoli, Julie Teruya-Feldstein, Henrik Sperber, Roberto Sanchez, Robert DeVita, Timothy J Martins, Omar Abdel-Wahab, Robert K Bradley, Eirini P Papapetrou
Connecting specific cancer genotypes with phenotypes and drug responses constitutes the central premise of precision oncology but is hindered by the genetic complexity and heterogeneity of primary cancer cells. Here, we use patient-derived induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 genome editing to dissect the individual contributions of two recurrent genetic lesions, the splicing factor SRSF2 P95L mutation and the chromosome 7q deletion, to the development of myeloid malignancy. Using a comprehensive panel of isogenic iPSCs-with none, one, or both genetic lesions-we characterize their relative phenotypic contributions and identify drug sensitivities specific to each one through a candidate drug approach and an unbiased large-scale small-molecule screen...
April 17, 2018: Stem Cell Reports
https://www.readbyqxmd.com/read/29677503/revolutionizing-precision-oncology-through-collaborative-proteogenomics-and-data-sharing
#5
Henry Rodriguez, Stephen R Pennington
The integration of proteomics into precision oncology presents opportunities that may transform the molecular analysis of cancer and accelerate basic and clinical cancer research. This Commentary discusses the importance of international collaboration and data sharing inspired by the Cancer Moonshot to accelerate the progress of multi-omic precision medicine-an approach that addresses the global diversity of people and of cancers.
April 19, 2018: Cell
https://www.readbyqxmd.com/read/29674173/precision-medicine-with-imprecise-therapy-computational-modeling-for-chemotherapy-in-breast-cancer
#6
REVIEW
Matthew T McKenna, Jared A Weis, Amy Brock, Vito Quaranta, Thomas E Yankeelov
Medical oncology is in need of a mathematical modeling toolkit that can leverage clinically-available measurements to optimize treatment selection and schedules for patients. Just as the therapeutic choice has been optimized to match tumor genetics, the delivery of those therapeutics should be optimized based on patient-specific pharmacokinetic/pharmacodynamic properties. Under the current approach to treatment response planning and assessment, there does not exist an efficient method to consolidate biomarker changes into a holistic understanding of treatment response...
April 16, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29673712/update-on-systemic-prostate-cancer-therapies-management-of-metastatic-castration-resistant-prostate-cancer-in-the-era-of-precision-oncology
#7
REVIEW
Philipp Nuhn, Johann S De Bono, Karim Fizazi, Stephen J Freedland, Maurizio Grilli, Philip W Kantoff, Guru Sonpavde, Cora N Sternberg, Srinivasan Yegnasubramanian, Emmanuel S Antonarakis
CONTEXT: Introduction of novel agents for the management of advanced prostate cancer provides a range of treatment options with notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At the same time, understanding of optimal patient selection, effective sequential use, and development of resistance patterns remains incomplete. OBJECTIVE: To review current systemic therapies and recent advances in drug development for mCRPC and strategies to aid in patient selection and optimal sequencing...
April 16, 2018: European Urology
https://www.readbyqxmd.com/read/29666822/accuracy-and-precision-of-a-veterinary-neuronavigation-system-for-radiation-oncology-positioning
#8
Isabelle F Vanhaezebrouck, Elizabeth A Ballegeer, Stephen Frey, Rob Sieffert
Conformal radiation treatment plans such as IMRT and other radiosurgery techniques require very precise patient positioning, typically within a millimeter of error for best results. CT cone beam, real-time navigation, and infrared position sensors are potential options for success but rarely present in veterinary radiation centers. A neuronavigation system (Brainsight Vet, Rogue Research) was tested 22 times on a skull for positioning accuracy and precision analysis. The first 6 manipulations allowed the authors to become familiar with the system but were still included in the analyses...
2018: Journal of Veterinary Medicine
https://www.readbyqxmd.com/read/29664813/development-and-validation-of-nomograms-predicting-overall-and-cancer-specific-survival-of-spinal-chondrosarcoma-patients
#9
Kehan Song, Jian Song, Xio Shi, Hongli Wang, Xiaosheng Ma, Xinlei Xia, Xin Liang, Kaiyuan Lin, Jianyuan Jiang
STUDY DESIGN: Retrospective analysis. OBJECTIVE: To develop and validate nomograms to predict overall survival (OS) and cancer-specific survival (CSS) of spinal chondrosarcoma patients. SUMMARY OF BACKGROUND DATA: In this era of personalized medicine, data those are available to predict the survival of spinal chondrosarcoma patients are still limited due to the rarity of the disease. Nomogram, which has been widely used in clinical oncology, could conveniently and precisely predict survival outcome for individual patient...
April 16, 2018: Spine
https://www.readbyqxmd.com/read/29662557/ct-radiomics-in-thoracic-oncology-technique-and-clinical-applications
#10
REVIEW
Geewon Lee, So Hyeon Bak, Ho Yun Lee
Precision medicine offers better treatment options and improved survival for cancer patients based on individual variability. As the success of precision medicine depends on robust biomarkers, the requirement for improved imaging biomarkers that reflect tumor biology has grown exponentially. Radiomics, the field of study in which high-throughput data are generated and large amounts of advanced quantitative features are extracted from medical images, has shown great potential as a source of quantitative biomarkers in the field of oncology...
April 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29659677/targeting-the-human-epidermal-growth-factor-receptor-2-her2-oncogene-in-colorectal-cancer
#11
S Siena, A Sartore-Bianchi, S Marsoni, H I Hurwitz, S J McCall, F Penault-Llorca, S Srock, A Bardelli, L Trusolino
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors are driven by amplification or mutation of HER2. MATERIALS AND METHODS: This paper reviews the role of HER2 as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type...
April 6, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29658474/-prospects-for-applications-in-human-health-of-nanopore-based-sequencing
#12
Christophe Audebert, David Hot, Ségolène Caboche
High throughput sequencing has opened up new clinical opportunities moving towards a medicine of precision. Oncology, infectious diseases or human genomics, many applications have been developed in recent years. The introduction of a third generation of nanopore-based sequencing technology, addressing some of the weaknesses of the previous generation, heralds a new revolution. Portability, real time, long reads and marginal investment costs, these promising new technologies point to a new shift of paradigm...
April 2018: Médecine Sciences: M/S
https://www.readbyqxmd.com/read/29648886/braf-adds-an-additional-piece-of-the-puzzle-to-precision-oncology-based-treatment-strategies-in-lung-cancer
#13
David Planchard, Bruce E Johnson
No abstract text is available yet for this article.
April 12, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29644557/colorectal-liver-metastases-does-the-future-of-precision-medicine-lie-in-genetic-testing
#14
Carlotta Barbon, Georgios Antonios Margonis, Nikolaos Andreatos, Neda Rezaee, Kazunari Sasaki, Stefan Buettner, Christos Damaskos, Timothy M Pawlik, Jin He, Christopher L Wolfgang, Matthew J Weiss
Colorectal liver metastases (CRLM) present an important clinical challenge in both surgical and medical oncology. Despite improvements in management, survival among patients undergoing resection of CRLM is still very variable and there is a paucity of clinical trial data and reliable biomarkers that could guide prognostic forecasts, treatment selection, and follow-up. Fortunately, recent advances in molecular biology and tumor sequencing have identified a number of critical genetic loci and proliferation markers that may hold the key to understanding the biologic behavior of CRLM; specifically, mutations of KRAS, BRAF, TP53, PIK3CA, APC, expression of Ki-67, and the presence of microsatellite instability appear to have a decisive impact on prognosis and response to treatment in patients with CRLM...
April 11, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29644010/value-based-genomics
#15
REVIEW
Jun Gong, Kathy Pan, Marwan Fakih, Sumanta Pal, Ravi Salgia
Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for clinical-decision making and research purposes. Despite the greater availability of tumor molecular profiling by next-generation sequencing at our doorsteps, the achievement of value-based care, or improving patient outcomes while reducing overall costs or risks, in the era of precision oncology remains a looming challenge...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29643841/mouse-models-that-enhanced-our-understanding-of-adult-t-cell-leukemia
#16
REVIEW
Sara Moodad, Abdou Akkouche, Rita Hleihel, Nadine Darwiche, Marwan El-Sabban, Ali Bazarbachi, Hiba El Hajj
Adult T cell Leukemia (ATL) is an aggressive lymphoproliferative malignancy secondary to infection by the human T-cell leukemia virus type I (HTLV-I) and is associated with a dismal prognosis. ATL leukemogenesis remains enigmatic. In the era of precision medicine in oncology, mouse models offer one of the most efficient in vivo tools for the understanding of the disease biology and developing novel targeted therapies. This review provides an up-to-date and comprehensive account of mouse models developed in the context of ATL and HTLV-I infection...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29628787/molecular-profiling-of-tumours-for-precision-oncology-high-hopes-versus-reality
#17
REVIEW
Sergiusz Nawrocki
Treatment based on molecular profiling of tumor is advertised however there are very limited clinical data supporting this approach so far. Only one, relatively small, randomized clinical trial (SHIVA) have not met its primary endpoint - prolongation of PFS. Some other unpublished series were reported during ASCO 2017 and are discussed in this review. There are many issues to be resolved before the tumor profiling will enter the clinical practice with significant benefit for patients, eg. spatial and temporal heterogeneity of tumor cells in individual patient, wide access to targeted therapies, toxicity of combined targeted therapies...
March 2018: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/29625053/comprehensive-characterization-of-cancer-driver-genes-and-mutations
#18
Matthew H Bailey, Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, Michael C Wendl, Jaegil Kim, Brendan Reardon, Patrick Kwok-Shing Ng, Kang Jin Jeong, Song Cao, Zixing Wang, Jianjiong Gao, Qingsong Gao, Fang Wang, Eric Minwei Liu, Loris Mularoni, Carlota Rubio-Perez, Niranjan Nagarajan, Isidro Cortés-Ciriano, Daniel Cui Zhou, Wen-Wei Liang, Julian M Hess, Venkata D Yellapantula, David Tamborero, Abel Gonzalez-Perez, Chayaporn Suphavilai, Jia Yu Ko, Ekta Khurana, Peter J Park, Eliezer M Van Allen, Han Liang, Michael S Lawrence, Adam Godzik, Nuria Lopez-Bigas, Josh Stuart, David Wheeler, Gad Getz, Ken Chen, Alexander J Lazar, Gordon B Mills, Rachel Karchin, Li Ding
Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few. We report a PanCancer and PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations. We identify 299 driver genes with implications regarding their anatomical sites and cancer/cell types...
April 5, 2018: Cell
https://www.readbyqxmd.com/read/29617658/machine-learning-detects-pan-cancer-ras-pathway-activation-in-the-cancer-genome-atlas
#19
Gregory P Way, Francisco Sanchez-Vega, Konnor La, Joshua Armenia, Walid K Chatila, Augustin Luna, Chris Sander, Andrew D Cherniack, Marco Mina, Giovanni Ciriello, Nikolaus Schultz, Yolanda Sanchez, Casey S Greene
Precision oncology uses genomic evidence to match patients with treatment but often fails to identify all patients who may respond. The transcriptome of these "hidden responders" may reveal responsive molecular states. We describe and evaluate a machine-learning approach to classify aberrant pathway activity in tumors, which may aid in hidden responder identification. The algorithm integrates RNA-seq, copy number, and mutations from 33 different cancer types across The Cancer Genome Atlas (TCGA) PanCanAtlas project to predict aberrant molecular states in tumors...
April 3, 2018: Cell Reports
https://www.readbyqxmd.com/read/29610396/precision-oncogenomics-in-pediatrics-a-personal-reflection
#20
Cindy Campbell, Jeffrey P Greenfield
Cindy Campbell, a bereaved parent who lost her son to a rare pediatric brain tumor, shares her experience and frustration over the lack of treatment options and minimal research funding in pediatric oncology. She invites Dr. Jeffrey P. Greenfield to reflect on the situation and share his professional experiences pertaining to advances in oncogenomics and pediatric brain tumors. They share a passion for making this technology available to all pediatric brain tumor patients in the future and using data to inform treatment protocols and improve outcomes...
April 2018: Cold Spring Harbor Molecular Case Studies
keyword
keyword
26135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"